28.01.2014 08:28:00
|
Daiichi Sankyo Company, Limited -- Moody's: FDA Prohibition Order on Ranbaxy' Toansa Plant Is Credit Negative for Daiichi Sankyo
Tokyo, January 28, 2014 -- The US Food and Drug Administration's (FDA) prohibition order on Ranbaxy's (not rated) Toansa facility due to quality issues is credit negative for Daiichi Sankyo (A1 stable), because it highlights continued challenges faced by Daiichi Sankyo and its ability to execute its long-term business strategy.